ARTHEx expands its Scientific Advisory Board with the appointment of Eric G. Marcusson, who has an extensive experience of more than 20 years in preclinical drug development of RNA therapeutics. Currently, Dr. Marcusson has his own consultancy firm to provide expert advice to start-ups, pharma industry and venture capitalists.
He is also co-founder and CSO of Providence Therapeutics (www.providencetherapeutics.com), specialized in mRNA vaccines. Previously, he held the role of scientific director at leading companies in the RNA therapeutics field, such as Regulus Therapeutics and Ionis Pharmaceuticals.
Dr. Beatriz Llamusí, CEO and co-founder of ARTHEx has said “We are thrilled to count on Dr. Marcusson’s advice. His experience in the design and preclinical development of antisense oligonucleotides will help us to move faster towards the clinical stages”.
